Jianing Ma

This publication record appears to combine work from multiple distinct research threads rather than a single focused program: large-scale global health burden studies (tuberculosis, HIV/AIDS, antimicrobial resistance, diarrhoeal disease) as part of the Global Burden of Disease collaboration, alongside separate lines on cancer/disease-related molecular pharmacology (natural compounds targeting proteins like ENO1 and PGK1), fungal biotechnology (Aspergillus niger enzyme engineering), and earlier clinical cardiology/echocardiography case studies. Prospective students should note the breadth spans epidemiology, pharmacology, biotechnology, and clinical medicine, suggesting this name may aggregate contributions from different projects or collaborators rather than one coherent lab focus.

Publication output has grown substantially over the last decade, rising from 0-2 papers per year around 2017-2019 to a peak of 12 in 2024, with a mean of about 6 papers per year over the last five years.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026